| Item Type | Name |
|
Concept
|
Antibodies, Neoplasm
|
|
Concept
|
Breast Neoplasms
|
|
Concept
|
DNA, Neoplasm
|
|
Concept
|
Myeloproliferative Disorders
|
|
Concept
|
Neoplasm Staging
|
|
Concept
|
Prostatic Neoplasms
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Drug Resistance, Neoplasm
|
|
Concept
|
Tumor Cells, Cultured
|
|
Concept
|
Neoplasms, Second Primary
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Cancer Vaccines
|
|
Concept
|
Bone Marrow Neoplasms
|
|
Concept
|
Early Detection of Cancer
|
|
Concept
|
Hematologic Neoplasms
|
|
Concept
|
Cell Line, Tumor
|
|
Concept
|
Genes, Neoplasm
|
|
Concept
|
Neoplasm Grading
|
|
Concept
|
Neoplasm Proteins
|
|
Concept
|
Neoplasms
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Myelodysplastic-Myeloproliferative Diseases
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
|
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
|
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
|
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
|
Academic Article
|
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
|
|
Academic Article
|
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
|
|
Academic Article
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
|
Academic Article
|
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
|
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Leukaemogenesis: more than mutant genes.
|
|
Academic Article
|
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity.
|
|
Academic Article
|
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
|
|
Academic Article
|
Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.
|
|
Academic Article
|
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
|
|
Academic Article
|
A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.
|
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
|
Academic Article
|
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
|
|
Academic Article
|
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
|
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
|
Academic Article
|
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
|
|
Academic Article
|
Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
|
|
Academic Article
|
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
|
|
Academic Article
|
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
|
|
Academic Article
|
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
|
|
Academic Article
|
Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.
|
|
Academic Article
|
Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms.
|
|
Academic Article
|
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
|
|
Academic Article
|
How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
|
|
Academic Article
|
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
|
|
Academic Article
|
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.
|
|
Academic Article
|
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
|
|
Academic Article
|
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.
|
|
Academic Article
|
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
|
|
Academic Article
|
Genomics of MPN progression.
|
|
Academic Article
|
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.
|
|
Academic Article
|
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
|
|
Academic Article
|
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
|
|
Academic Article
|
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
|
|
Academic Article
|
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
|
|
Academic Article
|
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
|
|
Academic Article
|
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
|
|
Academic Article
|
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
|
|
Academic Article
|
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.
|
|
Academic Article
|
SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
|
|
Academic Article
|
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
|
|
Academic Article
|
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
|
|
Academic Article
|
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
|
|
Academic Article
|
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
|
|
Academic Article
|
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
|
|
Academic Article
|
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
|
|
Academic Article
|
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
|